[1] MD B R H. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: What is new and what has changed? %J Cancer [J]. 2017, 123(3).
[2] R H B, K A E, C B K, et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. %J Thyroid : official journal of the American Thyroid Association [J]. 2016, 26(1).
[3] HJIYIANNAKIS P, MUNDY J, HARMER C. Thyroglobulin antibodies in differentiated thyroid cancer [J]. Clin Oncol, 1999, 11(4): 240-4.
[4] WESLLEY R P, SOUZA C M C, GABRIELA F M. Follow-up of patients with thyroid cancer and antithyroglobulin antibodies: a review for clinicians. %J Endocrine-related cancer [J]. 2021, 28(4).
[5] NETZEL B C, GREBE S K G, LEON B G C, et al. Thyroglobulin (Tg) Testing Revisited: Tg Assays, TgAb Assays, and Correlation of Results With Clinical Outcomes %J The Journal of Clinical Endocrinology & Metabolism [J]. 2015, 100(8).
[6] UMAL A, KYLE P, LEIGHA S, et al. Thyroglobulin Liquid Chromatography-Tandem Mass Spectrometry Has a Low Sensitivity for Detecting Structural Disease in Patients with Antithyroglobulin Antibodies. %J Thyroid : official journal of the American Thyroid Association [J]. 2017, 27(1).
[7] LEILA G, S K T, D N C C, et al. The role of a new polyclonal competitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer with structural disease but low levels of serum thyroglobulin by immunometric and LC-MS/MS methods. %J Endocrine [J]. 2020.
[8] A V F, MARKUS L, CRISTINA C, et al. Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. %J Thyroid : official journal of the American Thyroid Association [J]. 2013, 23(10).
[9] WESLLEY R P, MARINA C, FRANCO M G, et al. Comparison of Antithyroglobulin Antibody Concentrations Before and After Ablation with 131I as a Predictor of Structural Disease in Differentiated Thyroid Carcinoma Patients with Undetectable Basal Thyroglobulin and Negative Neck Ultrasonography. %J Thyroid : official journal of the American Thyroid Association [J]. 2016, 26(4).
[10] KIM W G, YOON J H, KIM W B, et al. Change of Serum Antithyroglobulin Antibody Levels Is Useful for Prediction of Clinical Recurrence in Thyroglobulin-Negative Patients with Differentiated Thyroid Carcinoma %J The Journal of Clinical Endocrinology & Metabolism [J]. 2008, 93(12).
[11] L D B, A V D H-S A N, J S W, et al. Clinical Applicability of Low Levels of Thyroglobulin Autoantibodies as Cutoff Point for Thyroglobulin Autoantibody Positivity. %J Thyroid : official journal of the American Thyroid Association [J]. 2019, 29(1).
[12] PIERPAOLO T, VALENTINA Z, MAURO I, et al. Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome. %J Clinical chemistry and laboratory medicine [J]. 2017, 55(12).
[13] GIANOUKAKIS A G. Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance? [J]. Curr Opin Oncol, 2015, 27(1): 26-32.
[14] G G A. Thyroglobulin antibody status and differentiated thyroid cancer: what does it mean for prognosis and surveillance? %J Current opinion in oncology [J]. 2015, 27(1).
[15] MORBELLI S, FERRARAZZO G, POMPOSELLI E, et al. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications [J]. J Endocrinol Invest, 2017, 40(4): 417-24.
[16] MATRONE A, LATROFA F, TORREGROSSA L, et al. Changing Trend of Thyroglobulin Antibodies in Patients With Differentiated Thyroid Cancer Treated With Total Thyroidectomy Without I-131 Ablation [J]. Thyroid, 2018, 28(7): 871-9.
[17] ZAVALA L F, BARRA M I, OLMOS R, et al. In properly selected patients with differentiated thyroid cancer, antithyroglobulin antibodies decline after thyroidectomy and their sole presence should not be an indication for radioiodine ablation [J]. Arch Endocrinol Metab, 2019, 63(3): 293-9.
[18] SEO J H, LEE S W, AHN B C, et al. Recurrence detection in differentiated thyroid cancer patients with elevated serum level of antithyroglobulin antibody: special emphasis on using 18F-FDG PET/CT [J]. Clin Endocrinol, 2010, 72(4): 558-63.
[19] REVERTER J L, ROSAS-ALLENDE I, PUIG-JOVE C, et al. Prognostic Significance of Thyroglobulin Antibodies in Differentiated Thyroid Cancer [J]. J Thyroid Res, 2020, 2020: 6.
[20] MCLEOD D S A, COOPER D S, LADENSON P W, et al. Prognosis of Differentiated Thyroid Cancer in Relation to Serum Thyrotropin and Thyroglobulin Antibody Status at Time of Diagnosis [J]. Thyroid, 2014, 24(1): 35-42.
[21] GORGES R, MANIECKI M, JCNTZEN W, et al. Development and clinical impact of thyroglobulin antibodies in patients with differentiated thyroid carcinoma during the first 3 years after thyroidectomy [J]. Eur J Endocrinol, 2005, 153(1): 49-55.
[22] LEE Z J O, ESLICK G D, EDIRIMANNE S. Investigating Antithyroglobulin Antibody As a Prognostic Marker for Differentiated Thyroid Cancer: A Meta-Analysis and Systematic Review [J]. Thyroid, 2020, 30(11): 1601-12.
[23] TRIMBOLI P, ZILIOLI V, IMPERIALI M, et al. Thyroglobulin autoantibodies before radioiodine ablation predict differentiated thyroid cancer outcome [J]. Clin Chem Lab Med, 2017, 55(12): 1995-2001.